HMGB1 and ovarian carcinoma: Another report about measurement of HMGB1 concentrations in the serum samples of 105 patients with ovarian cancer, 46 patients with benign ovarian disease and 33 healthy controls is consistent with our results and showed significantly elevated HMGB1 levels in malignant cases, yet no ROCs or sensitivities were reported [36].